Glypvilo (Vildagliptin)

Glypvilo is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive glycemic control strategy.

• Used in adults with type 2 diabetes when diet and exercise alone are insufficient.
• Can be combined with other oral antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones.
• May be considered when a patient requires a DPP‑4 inhibitor to improve post‑prandial glucose control.
• Intended for use in conjunction with lifestyle modifications, including diet and physical activity.

Like all medications, Glypvilo may cause side effects, which are generally categorized by frequency and severity.

Common

• Upper respiratory tract infection.
• Headache.
• Nasopharyngitis.
• Mild gastrointestinal discomfort such as nausea or abdominal pain.

Serious

• Pancreatitis (severe abdominal pain).
• Severe allergic reactions, including angioedema or anaphylaxis.
• Hepatic dysfunction.
• Hypersensitivity rash or skin eruptions.

Healthcare providers should assess several precautionary factors before prescribing Glypvilo to ensure safe use.

• Evaluate renal function, as dose adjustment may be required in impaired kidneys.
• Review hepatic status, especially in patients with a history of liver disease.
• Monitor for signs of pancreatitis, including persistent abdominal pain.
• Use cautiously in patients with a history of severe allergic reactions.
• Consider pregnancy and breastfeeding status; safety data are limited.
• Assess overall cardiovascular risk, although no specific contraindication is established.

Glypvilo can interact with other medicines, influencing its effectiveness or increasing the risk of adverse events.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise vildagliptin levels.
• Concomitant use with other DPP‑4 inhibitors, as combined effect is not recommended.
• Medications known to cause pancreatitis (e.g., GLP‑1 receptor agonists).

Use with caution

• Diuretics, especially thiazides, which may affect blood glucose control.
• Anticoagulants, as glycemic fluctuations can alter INR.
• Beta‑blockers, which may mask hypoglycemia symptoms.
• NSAIDs, which can affect renal function when combined with vildagliptin in patients with renal impairment.